{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:29Z","timestamp":1786991129457,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115935","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:23:20Z","timestamp":1764577400000},"page":"115935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Febuxostat alleviates gout-associated hyperuricemia and inflammation by downregulating IL1A to modulate TLR2\/TLR4\/NF-\u03baB signaling pathway"],"prefix":"10.1016","volume":"168","author":[{"given":"Mengting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115935_bb0005","doi-asserted-by":"crossref","unstructured":"Dissanayake LV, Spires DR, Palygin O, Staruschenko A. Effects of uric acid dysregulation on the kidney. Am. J. Physiol.-Renal Physiol. 2020;318(5):F1252-F7.1.","DOI":"10.1152\/ajprenal.00066.2020"},{"issue":"3","key":"10.1016\/j.intimp.2025.115935_bb0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4049\/jimmunol.2000319","article-title":"Soluble uric acid is an intrinsic negative regulator of monocyte activation in monosodium urate crystal\u2013induced tissue inflammation","volume":"205","author":"Ma","year":"2020","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2025.115935_bb0015","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3390\/nu14173590","article-title":"Moving the needle in gout management: the role of culture, diet, genetics, and personalized patient care practices","volume":"14","author":"Roman","year":"2022","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.intimp.2025.115935_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3899\/jrheum.190257","article-title":"Rising incidence of acute hospital admissions due to gout","volume":"47","author":"Russell","year":"2020","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115935_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185x.70375","article-title":"2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: recommendations for general patients","volume":"28","author":"Sun","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2025.115935_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105826","article-title":"Optimizing gout treatment: a comprehensive review of current and emerging uricosurics","volume":"92","author":"Kaufmann","year":"2025","journal-title":"Joint Bone Spine"},{"issue":"12","key":"10.1016\/j.intimp.2025.115935_bb0035","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200666120-00002","article-title":"Pathophysiology, clinical presentation and treatment of gout","volume":"66","author":"Teng","year":"2006","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14656566.2024.2442028","article-title":"An update on the pharmacotherapy of gout","volume":"26","author":"Yuan","year":"2025","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2025.115935_bb0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.14412\/1996-7012-2021-2-50-56","article-title":"Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data)","volume":"15","author":"Chikina","year":"2021","journal-title":"Mod. Rheumatol. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41598-021-04125-7","article-title":"Degenerative joint disease induced by repeated intra-articular injections of monosodium urate crystals in rats as investigated by translational imaging","volume":"12","author":"Accart","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0055","article-title":"MSU crystals induce sterile IL-1\u03b2 secretion via P2X7 receptor activation and HMGB1 release","volume":"1864","author":"Marinho","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0060","article-title":"The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.intimp.2025.115935_bb0065","article-title":"Anti-hyperuricemic and nephroprotective effects of dihydroberberine in potassium oxonate-and hypoxanthine-induced hyperuricemic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115935_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117223","article-title":"Identification of a novel xanthine oxidoreductase inhibitor for hyperuricemia treatment with high efficacy and safety profile","volume":"178","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2025.115935_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5455\/medarh.2020.74.172-176","article-title":"Comparison of the effects of allopurinol and Febuxostat on the values of triglycerides in Hyperuricemic patients","volume":"74","author":"Ziga-Smajic","year":"2020","journal-title":"Med. Arch."},{"issue":"6","key":"10.1016\/j.intimp.2025.115935_bb0080","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.12669\/pjms.36.6.2945","article-title":"Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis","volume":"36","author":"Zhang","year":"2020","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.intimp.2025.115935_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40744-019-00173-8","article-title":"A randomized, double-blind, non-inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout","volume":"6","author":"Zhang","year":"2019","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7150\/ijms.88447","article-title":"IL1A regulates the inflammation in gout through the toll-like receptors pathway","volume":"21","author":"Ling","year":"2024","journal-title":"Int. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115935_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/md19050238","article-title":"Fucoidan from Laminaria japonica inhibits expression of GLUT9 and URAT1 via PI3K\/Akt, JNK and NF-\u03baB pathways in uric acid-exposed HK-2 cells","volume":"19","author":"Zhang","year":"2021","journal-title":"Mar. Drugs"},{"issue":"Pt 1","key":"10.1016\/j.intimp.2025.115935_bb0100","article-title":"Effects and mechanisms of Polygonati Rhizoma polysaccharide on potassium oxonate and hypoxanthine-induced hyperuricemia in mice","volume":"280","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115935_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/nep.14159","article-title":"Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K\/AKT\/NF-\u03baB signalling pathway","volume":"28","author":"Liu","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.intimp.2025.115935_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116777","article-title":"Shizhifang ameliorates pyroptosis of renal tubular epithelial cells in hyperuricemia through inhibiting NLRP3 inflammasome","volume":"317","author":"Zhou","year":"2023","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115935_bb0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2017.20189","article-title":"Lesinurad\/allopurinol (Duzallo) for gout-associated hyperuricemia","volume":"319","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.intimp.2025.115935_bb0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.omtm.2020.11.007","article-title":"qPCR and qRT-PCR analysis: regulatory points to consider when conducting biodistribution and vector shedding studies","volume":"20","author":"Ma","year":"2021","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.intimp.2025.115935_bb0125","first-page":"26","article-title":"Crystals of pain: navigating gout and its management","volume":"91","author":"Vambe","year":"2024","journal-title":"SA Pharm. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cab\u0103u","year":"2020","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2025.115935_bb0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/1744666X.2021.1937129","article-title":"Regulation of crystal induced inflammation: current understandings and clinical implications","volume":"17","author":"Galozzi","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2025.115935_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213005","article-title":"Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout","volume":"139","author":"Chen","year":"2022","journal-title":"Biomater. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/molecules25010046","article-title":"Design and biological evaluation of colchicine-CD44-targeted peptide conjugate in an in vitro model of crystal induced inflammation","volume":"25","author":"Zoghebi","year":"2019","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.intimp.2025.115935_bb0150","doi-asserted-by":"crossref","DOI":"10.21037\/apm-20-2072","article-title":"Treatment of refractory gout with TNF-\u03b1 antagonist etanercept combined with febuxostat","volume":"9","author":"Zhang","year":"2020","journal-title":"Ann. Palliat. Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.115935_bb0155","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2025.115935_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.134782","article-title":"Polysaccharides from Alpinia oxyphylla fruit prevent hyperuricemia by inhibiting uric acid synthesis, modulating intestinal flora and reducing renal inflammation","volume":"278","author":"Ren","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115935_bb0165","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s10067-020-05090-8","article-title":"Gout: a disease involved with complicated immunoinflammatory responses: a narrative review","volume":"39","author":"Wu","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115935_bb0175","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.biopha.2018.06.163","article-title":"Research on the pharmacodynamics and mechanism of Fraxini cortex on hyperuricemia based on the regulation of URAT1 and GLUT9","volume":"106","author":"Zhou","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115935_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106405","article-title":"Pharmacological evaluation of a novel skeleton compound isobavachin (4\u2032, 7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: dual actions of URAT1\/GLUT9 and xanthine oxidase inhibitory activity","volume":"133","author":"Zhao","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"12_suppl","key":"10.1016\/j.intimp.2025.115935_bb0185","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1177\/09603271211045953","article-title":"Mitigation of IL-1\u03b2, IL-6, TNF-\u03b1, and markers of apoptosis by ursolic acid against cisplatin-induced oxidative stress and nephrotoxicity in rats","volume":"40","author":"Tripathi","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"issue":"17","key":"10.1016\/j.intimp.2025.115935_bb0190","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/ijms21176009","article-title":"Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies","volume":"21","author":"Gelfo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115935_bb0195","unstructured":"J. Friscic, Synovial Fibroblasts Shape Local Inflammatory Responses in the Joint: Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany), 2022."},{"issue":"15","key":"10.1016\/j.intimp.2025.115935_bb0200","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.3390\/ijms21155386","article-title":"NLRP3 inflammasome-mediated inflammation in acute pancreatitis","volume":"21","author":"Ferrero-Andr\u00e9s","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"44","key":"10.1016\/j.intimp.2025.115935_bb0205","article-title":"The interleukin-1 receptor\/toll-like receptor superfamily: signal transduction during inflammation and host defense","volume":"2000","author":"O\u2019Neill","year":"2000","journal-title":"Sci. STKE"},{"issue":"4","key":"10.1016\/j.intimp.2025.115935_bb0210","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1074\/jbc.M113.521161","article-title":"Lipopolysaccharide activates toll-like receptor 4 (TLR4)-mediated NF-\u03baB signaling pathway and proinflammatory response in human pericytes","volume":"289","author":"Guijarro-Mu\u00f1oz","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0215","article-title":"Integrated molecular docking with network pharmacology to reveal the molecular mechanism of simiao powder in the treatment of acute gouty arthritis","volume":"2021","author":"Fan","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0220","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1038\/s41598-018-27956-3","article-title":"Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: a population based study","volume":"8","author":"Yan","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11655-022-3720-7","article-title":"Effect of berberine on activation of TLR4-NF\u03baB signaling pathway and NLRP3 inflammasome in patients with gout","volume":"29","author":"Dang","year":"2023","journal-title":"Chin. J. Integr. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115935_bb0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jlb.67.4.508","article-title":"The interleukin-1 receptor\/toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products","volume":"67","author":"Bowie","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2025.115935_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-020-04312-x","article-title":"Cryptosporidium parvum upregulates miR-942-5p expression in HCT-8 cells via TLR2\/TLR4-NF-\u03baB signaling","volume":"13","author":"Zhang","year":"2020","journal-title":"Parasit. Vectors"},{"issue":"8","key":"10.1016\/j.intimp.2025.115935_bb0240","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/cells9081910","article-title":"TLR3-dependent activation of TLR2 endogenous ligands via the MyD88 signaling pathway augments the innate immune response","volume":"9","author":"Teixeira","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.115935_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679106","article-title":"NF-\u03baB and its regulators during pregnancy","volume":"12","author":"G\u00f3mez-Ch\u00e1vez","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115935_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300582","article-title":"Correlation analysis of serum TLR4 protein levels and TLR4 gene polymorphisms in gouty arthritis patients","volume":"19","author":"Liu","year":"2024","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2025.115935_bb0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-024-03335-4","article-title":"Deficiency of histone deacetylases 3 in macrophage alleviates monosodium urate crystals-induced gouty inflammation in mice","volume":"26","author":"Yang","year":"2024","journal-title":"Arthritis Res. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501923X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501923X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:01:05Z","timestamp":1771513265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501923X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S156757692501923X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115935","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat alleviates gout-associated hyperuricemia and inflammation by downregulating IL1A to modulate TLR2\/TLR4\/NF-\u03baB signaling pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115935"}}